TICKERNERD
Menu
SOLVSOLVHealthcare · Medical Instruments & Supplies

SOLV Stock Forecast: Solventum Corp. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$88
+0.20% on the day

The 15 Wall Street analysts covering Solventum Corp. hold a median 12-month price target of $95 — +7.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 3 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$15.0B
Ticker Nerd rank
92 / 100
Median analyst target
$95
Analysts covering
15
Revenue$2.2B+2.2% y/y
Operating income$181.0M
Net income$93.0M
Free cash flow$144.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.7%
1M
−4.0%
YTD
+11.1%
1Y
+19.0%
From 52W high
−4.8%
From 52W low
+40.9%
$62
$92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SOLV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Solventum Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
98
Revisions
89
Value
87
Momentum
75
Volatility
73
Growth
68
Quality
59
Accruals
53
Size
12

Issuance (98): The share count has been shrinking and the company is not leaning on new borrowing.

Accruals (53): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SOLV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SOLV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100$110$120Jan 26Apr 26Jul 26Oct 26SOLVHigh $113Median $95Low $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
8 Buy5 Hold2 Sell
Low $70Median $95High $113

The green dot is the last close — the median target sits +7.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Sept 2026BTIGReiteratesBuy$95
6 Aug 2026BTIGMaintainsBuy—
6 Aug 2026BTIGMaintainsBuy$91 → $95
6 Aug 2026KeybancMaintainsOverweight—
6 Aug 2026KeybancMaintainsOverweight$93 → $102
6 Aug 2026Piper SandlerMaintainsOverweight—
6 Aug 2026Piper SandlerMaintainsOverweight$92 → $105
6 Aug 2026StifelMaintainsBuy—
6 Aug 2026StifelMaintainsBuy$90 → $100
6 Aug 2026UBSMaintainsBuy—
6 Aug 2026UBSMaintainsBuy$95 → $101
6 Aug 2026WedbushMaintainsOutperform—
6 Aug 2026WedbushMaintainsOutperform$94 → $101
28 July 2026UBSUpgradeBuy$95
28 July 2026UBSUpgradeBuy—
9 July 2026BMO CapitalInitiatesMarket Perform—
15 May 2026WedbushInitiatesOutperform—
6 May 2026BTIGReiteratesBuy—
6 May 2026KeybancMaintainsOverweight—
6 May 2026StifelMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SOLV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SOLV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Solventum Corp. returned +19.0% against +16.2% for the S&P 500, dividends included.

SOLV vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Jan 26Apr 26Jul 26Oct 26SOLVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SOLV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+9.0%
Analysts raising
14
Analysts cutting
0
Fundamentals

Solventum Corp. (SOLV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
10.7×

Cheaper than 56% of US stocks

Price / sales
1.8×

Cheaper than 54% of US stocks

Price / book
3.1×

Cheaper than 31% of US stocks

EV / EBITDA
17.4×

Cheaper than 18% of US stocks

Growth & margins
Revenue growth (YoY)
2.2%

Higher than 32% of US stocks

Earnings growth (YoY)
2.2%

Higher than 39% of US stocks

Gross margin
58.2%

Higher than 72% of US stocks

Operating margin
9.8%

Higher than 64% of US stocks

Net margin
17.3%

Higher than 80% of US stocks

Returns & dividend
Return on equity
34.0%

Higher than 89% of US stocks

Return on assets
2.7%

Higher than 63% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Solventum Corp. (SOLV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Solventum Corp. has a market value of $15.0B and an enterprise value of $19.8B.

  • Revenue in the twelve months to 30 June 2026: $8.3B. The latest quarter grew 2.2% year on year.

  • Net income over the same four quarters: $1.4B, a 17.3% net margin.

  • Diluted earnings per share, trailing twelve months: $8.18.

  • Free cash flow in the twelve months to 30 June 2026: −$118.0M.

  • Shares outstanding: 170.1M.

  • Trailing P/E: 10.7×; forward P/E: 12.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Solventum Corp. employs 20,584 people — $404K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Oct 2026

Data provided by Twelve Data

Peers

SOLV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
SOLVSolventum Corp.$15.0B
92
BAXBaxter International, Inc.$12.1B
90
COOThe Cooper Cos., Inc.$11.2B
71
AVTRAvantor, Inc.$10.5B
82
ALGNAlign Technology, Inc.$10.3B
84
RGENRepligen Corp.$10.2B
92
WSTWest Pharmaceutical Services, Inc.$26.3B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Solventum Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SOLV news & analysis

Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names

Zacks Investment Research · 5 Oct 2026positive

Zacks Investment Research highlights two medical names with positive earnings momentum, suggesting they are expected to beat quarterly earnings estimates based on the Zacks Earnings ESP tool. The article directs investors to stocks with favorable earnings surprise potential.

Why it matters — A SOLV watcher would care because positive earnings momentum may be relevant to the company's near-term earnings outlook and analyst expectations.

Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play

Seeking Alpha · 18 Sept 2026positive

Solventum is trading at a discount to medical technology peers and is pursuing portfolio optimization, including a possible spin-off of its Health Information Systems segment. The company also raised its 2026 EPS guidance to $7.10-$7.20 and operating margin guidance to 22.2%-22.7%.

Why it matters — SOLV watchers would care because the company's margin-expansion guidance and potential divestiture signal a strategy aimed at narrowing its valuation gap to med-tech peers and reducing debt.

Here's Why You Should Hold Solventum Stock in Your Portfolio for Now

Zacks Investment Research · 17 Sept 2026positive

Zacks reports that Solventum's strong second-quarter performance, growth investments, and cost-saving program support its outlook. However, higher raw material costs remain a concern for the company.

Why it matters — The news highlights both the supporting factors behind Solventum's current outlook and a key cost concern, giving watchers a balanced view of the company's near-term prospects.

Here's Why Solventum (SOLV) is a Strong Value Stock

Zacks Investment Research · 17 Sept 2026positive

Zacks Investment Research highlighted Solventum (SOLV) as a strong value stock using its Zacks Style Scores system, which is designed to identify market-beating stocks for investment portfolios.

Why it matters — A SOLV watcher would care because the stock is being flagged favorably by a widely followed screening methodology for value-oriented investors.

Why Solventum (SOLV) is a Top Stock for the Long-Term

Zacks Investment Research · 15 Sept 2026positive

Zacks Investment Research highlights Solventum as a top long-term stock, featuring it via the Focus List in its Zacks Premium portfolio service, which aims to identify strong, market-beating stocks with positive earnings outlooks.

Why it matters — A Solventum watcher would note that the company has been singled out by a respected research service for its positive earnings outlook and long-term potential.

FAQ

Frequently asked questions about SOLV stock

What is the SOLV stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Solventum Corp. have a median 12-month price target of $95, with estimates ranging from $70 to $113. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SOLV stock a buy right now?

Of the 15 analysts covering Solventum Corp., 8 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Solventum Corp. 92 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SOLV?

As at 3 Oct 2026, Solventum Corp. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (98 of 100).

Will SOLV stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +7.9% from the last close, and Ticker Nerd's factor model ranks Solventum Corp. 92 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SOLV stock forecast for 2030?

No analyst covering Solventum Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $113 over the next 12 months.

How has SOLV stock performed over the past year?

Solventum Corp. returned +19.0% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Solventum Corp. do?

Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V.

What is the latest news on SOLV?

The most recent item we track (Zacks Investment Research, 5 Oct 2026): "Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names". Zacks Investment Research highlights two medical names with positive earnings momentum, suggesting they are expected to beat quarterly earnings estimates based on the Zacks Earnings ESP tool. The article directs investors to stocks with favorable earnings surprise potential.

Company

About Solventum Corp.

Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, and medical electrodes. The Dental Solutions segment offers products used in restorative and orthodontic workflows, including brackets, aligners, cements, and bonding agents. Through Health Information Systems, Solventum supplies software and services that support physician documentation, coding automation, speech recognition, and data visualization for healthcare organizations. The company serves customers in the United States and internationally through direct sales, distribution, key account management, inside sales, and e-commerce. Headquartered in Eagan, Minnesota, Solventum focuses on technologies that support safer, more efficient healthcare delivery.

CEO Mr. Bryan C. Hanson · 20,584 employees · United States · https://www.solventum.com